Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286843 · ClinicalTrials.gov registry record · NA
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT02286843: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02286843 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02286843, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines that attack HER2, but we do not know why or which patients will benefit. This study uses a new imaging method, HER2-targeted PET/CT, to identify patients that may benefit from medicines that attack HER2. This is experimental.
Interventions
- DEVICE PET/CT scan
- RADIATION 89Zr-trastuzumab
- RADIATION 89Zr-pertuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2014-11-06 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02286843
The ClinicalTrials.gov registry entry for NCT02286843 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PET/CT scan is the first listed.
NCT02286843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02286843 about?
NCT02286843 is a clinical study titled "Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?". Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines ...
What is the current status of trial NCT02286843?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2014-11-06. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT02286843?
The interventions under investigation include: PET/CT scan (DEVICE), 89Zr-trastuzumab (RADIATION), 89Zr-pertuzumab (RADIATION).
Who is sponsoring clinical trial NCT02286843?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.